Eli Lilly and Company Aktie News

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-breaking oral presentation at the 2025 American Society of Hematology Annual Meeting and Exposition, and were featured as part of the meeting's press...

Eli Lilly (LLY) is set to add Mounjaro to China's national reimbursement list, dramatically expanding its reach in the diabetes market. LLY's bull case hinges on securing reimbursement for Mounjaro's obesity and sleep apnea indications, unlocking multi-billion-dollar addressable markets even at low adoption rates. Despite trading at a premium (42.7x forward P/E), LLY's robust earnings growth pr...

Stock splits may not alter a company's fundamentals, but keeping an eye on stocks that are likely to experience a split could be a profitable move. Dutch semiconductor manufacturing equipment maker ASML Holding now trades for over $1,100 per share.

I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currently offer estimated future returns of at least 10%, with 18 appearing potentially undervalued per my Free Cash Flow model. Top-ranked names like ResMed, Mastercard, and MSCI combine strong projected ...

INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.

INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D.

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets.

Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with type 2 diabetes, the National Healthcare Security Administration said in a website notice on Sunday.